ArticleCommunications biology2026
Repurposing Azeliragon as a novel antibacterial agent against methicillin-resistant Staphylococcus aureus via combined membrane phospholipids and cell wall targeting.
Junhua Ma, Yuqing Xia, Jintuan Lin, Chengchun Chen, Qingyin Meng, Zhijian Yu, Lili Ouyang, Bao Chai, Bing Bai, TieYing Hou and 1 more
Abstract read
In one paragraphArticle in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Junhua Ma *Department of Infectious Diseases and Shenzhen Key Laboratory for Endogenous Infections, Shenzhen Nanshan People's Hospital, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen, China.
Yuqing Xia *Department of Infectious Diseases and Shenzhen Key Laboratory for Endogenous Infections, Shenzhen Nanshan People's Hospital, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen, China.
Jintuan Lin *Department of Critical Care Medicine, Shenzhen Nanshan People's Hospital, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen, China.
Chengchun Chen *Department of Infectious Diseases and Shenzhen Key Laboratory for Endogenous Infections, Shenzhen Nanshan People's Hospital, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen, China.
Qingyin MengDepartment of Infectious Diseases and Shenzhen Key Laboratory for Endogenous Infections, Shenzhen Nanshan People's Hospital, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen, China.
Zhijian YuDepartment of Infectious Diseases and Shenzhen Key Laboratory for Endogenous Infections, Shenzhen Nanshan People's Hospital, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen, China.
Lili OuyangDepartment of Critical Care Medicine, Shenzhen Nanshan People's Hospital, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen, China.
Bing BaiDepartment of Infectious Diseases and Shenzhen Key Laboratory for Endogenous Infections, Shenzhen Nanshan People's Hospital, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen, China. 568646535@qq.com.ORCID http://orcid.org/0000-0002-6744-9860 TieYing HouDepartment of Infectious Diseases and Shenzhen Key Laboratory for Endogenous Infections, Shenzhen Nanshan People's Hospital, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen, China. sz_houtieying@yeah.net.ORCID http://orcid.org/0000-0002-8765-9339 Zewen WenDepartment of Infectious Diseases and Shenzhen Key Laboratory for Endogenous Infections, Shenzhen Nanshan People's Hospital, Affiliated Nanshan Hospital of Shenzhen University, Shenzhen, China. wenzw05@163.com.ORCID http://orcid.org/0000-0002-9934-2056 Funding
Shenzhen Science and Technology Innovation Commission JCYJ20240813114503005Shenzhen Science and Technology Innovation Commission JCYJ20240813114518024Shenzhen Science and Technology Innovation Commission JCYJ20240813114606009
6 · The paper itselfAbstract
Methicillin-resistant Staphylococcus aureus (MRSA) poses a persistent clinical threat due to limited therapeutic options and the rapid emergence of resistance. Azeliragon, an orally bioavailable Receptor for Advanced Glycation End-products (RAGE) inhibitor previously tested in human trials, was identified as a potential antibacterial agent against MRSA through high-throughput screening. It exhibited potent antibacterial activity against clinical S. aureus isolates (MIC
Indexed as
Anti-Bacterial AgentsCell WallMembrane LipidsMethicillin-Resistant Staphylococcus aureusPhospholipidsAnimalsBiofilmsHumansMiceMicrobial Sensitivity TestsStaphylococcal InfectionsAnti-Bacterial AgentsMembrane LipidsPhospholipids
Identifiers
PMID42135462
PMCPMC13408685
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390